TORECAN
LOE ApproachingNDAORALTABLET
Approved
Jul 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORECAN is an oral small-molecule tablet approved by Novartis in 1961 with an unknown mechanism of action and indication profile. The drug's specific therapeutic use and patient population cannot be determined from available data, though its longevity suggests established clinical utility in a legacy indication.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%), indicating potential team downsizing or transition focus toward lifecycle extension or new formulations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggest limited active hiring; working on TORECAN offers stable maintenance responsibilities in a legacy product with predictable, routine commercial execution. Career growth opportunities are constrained by LOE proximity and minimal clinical development.
Brand ManagerField Sales Representative
Worked on TORECAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.